Home Blog Page 2046

Concord Medical Reports Financial Results for the First Half of 2025

BEIJING, Sept. 26, 2025 /PRNewswire/ — Concord Medical Services Holdings Limited (“Concord Medical” or the “Company”) (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention in China, today announced its unaudited consolidated financial results for the six months ended June 30, 2025[1].

2025 First Half Highlights

  • Total net revenues were RMB200.6 million (US$28.0 million) in the first half of 2025, representing a 8.3% decrease from total net revenues of RMB218.8 million in the same period last year. Total net revenues included the net revenues from the hospital business of RMB153.0 million (US$21.4 million) and the net revenues from the network business of RMB47.6 million (US$6.6 million).
  • Gross loss was RMB4.3 million (US$0.6 million) in the first half of 2025, compared to the gross loss of RMB41.6 million in the first half of 2024. The gross loss margin was 2.1% for the first half of 2025, compared to 19.0% for the same period last year.
  • Net loss attributable to ordinary shareholders in the first half of 2025 was RMB27.1 million (US$3.8 million), compared to RMB172.3 million in the same period last year.
  • Basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2025 were both RMB0.21 (US$0.03), compared to RMB1.31 in the same period last year.
  • Adjusted EBITDA[2] was negative RMB62.2 million (US$8.7 million) in the first half of 2025, compared to negative RMB148.0 million in the same period last year.

[1] This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted, all translations of RMB into U.S. dollars are made at a rate of RMB7.1636 to US$1.00, the noon buying rate in New York City for cable transfers payable in RMB, as certified for customs purposes by the Federal Reserve Bank of New York on June 30, 2025.

[2] Adjusted EBITDA is defined as net income/(loss) plus interest expenses, net, income tax expenses, depreciation and amortization and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.

Dr. Jianyu Yang, Chairman and Chief Executive Officer of Concord Medical, commented, “The precision of proton therapy helps prevent long-term damage to critical functional areas—including the brain, heart, and rectum—while allowing clinicians to safely escalate radiation doses to target sites to improve efficacy in refractory cancers. With minimal impact on surrounding normal tissues, patients benefit from fewer side effects and faster recovery, making proton therapy an optimal treatment option in cases where balancing efficacy and safety is critical.

As the first proton therapy center in South mainland China to commence clinical operations, Guangzhou Concord Cancer Hospital has developed specialized treatment protocols for a range of malignancies. In patients with nasopharyngeal carcinoma, aged between 10 and 71, we observed significant tumor regression, with elderly patients experiencing only mild mucosal reactions. For central nervous system tumors, the hospital achieved successful functional preservation even in extensive irradiation fields such as whole-brain and whole-spine treatments. In pediatric care, as of June 30, the Company treated its youngest proton therapy patient, a child of just over one year old. Through advanced radiotherapy techniques and careful anesthetic management, the hospital was able to provide effective protection and treatment.

These results highlight the clinical value of proton therapy in improving outcomes for challenging cancers while preserving function in critical organs. Looking forward, the Company will remain committed to advancing proton therapy, enhancing public understanding of precision radiotherapy, strengthening patient confidence, and expanding patient access to internationally advanced diagnostic and therapeutic technologies, innovative medications, and patient-centered care.”

2025 First Half Financial Results

Net Revenues

Hospital Business

Net revenues from the hospital business were RMB153.0 million (US$21.4 million) in the first half of 2025, representing a 11.1% increase from net revenues of RMB137.8 million in the first half of 2024, mainly because of the commencement of proton therapy operations at Guangzhou Concord Cancer Hospital.

Network Business

Net revenues from the network business were RMB47.6 million (US$6.6 million), representing a 41.3% decrease from net revenues of RMB81.0 million in the first half of 2024, mainly because (1) demand for medical equipment and software decreased under the current macroeconomic environment, leading to delayed overall business demand, and (2) operating lease revenue decreased since this is no longer the Company’s main business and expired contracts were not renewed.

Cost of Revenues

Hospital Business

Cost of revenues of the hospital business in the first half of 2025 was RMB157.2 million (US$21.9 million), representing a 9.6% decrease from cost of revenues of RMB174.0 million in the first half of 2024, mainly because (1) efficiency of human resources improved as the Company implemented a strategy focused on enhancing operational efficiency and reducing costs, (2) consumables cost, maintenance cost and lease cost decreased along with the development of the hospital business.

Network Business

Cost of revenues of the network business was RMB47.7million (US$6.7 million), representing a 44.8% decrease from RMB86.4 million in the first half of 2024, mainly because of the decrease in cost as a result of the decrease in revenue generated from sales and installation of medical equipment and software, and from management and technical support services.

Gross Loss and Gross Loss Margin

Gross loss from the operating business was RMB4.3million (US$0.6 million) in the first half of 2025, compared to RMB41.6 million in the same period last year. The gross loss margin for the first half of 2025 was 2.1%, compared to the gross loss margin of 19.0% for the same period last year. The improvement in gross loss margin of the operating business was mainly because of adjustments in the Company’s revenue structure, with the commencement of the proton therapy business bringing efficiency improvements, and the strategic focus on enhancing operational efficiency and reducing costs.

Operating Expenses

Selling expenses were RMB21.0 million (US$2.9 million) in the first half of 2025, compared to RMB25.0 million in the first half of 2024. Selling expenses as a percentage of net revenues was 10.5% in the first half of 2025, compared to 11.4% in the first half of 2024.

General and administrative expenses were RMB119.4 million (US$16.7 million) in the first half of 2025, of which employee benefit expenses were RMB51.0 million (US$7.1 million). In the same period of last year, general and administrative expenses were RMB131.2 million. The decrease was mainly attributable to the decrease in staff cost and listing expenses, and the strategic focus on enhancing operational efficiency and reducing costs. General and administrative expenses as a percentage of net revenues were 59.5% in the first half of 2025, compared to 59.9% in the first half of 2024.

Capital Expenditures

Comparing to RMB168.4 million in the first half of 2024, capital expenditures were RMB100.6 million (US$14.0 million) in the first half of 2025, mainly due to the decrease in deposit for equipment and construction fees for our hospital business.

Bank Loans and Other Borrowings

As of June 30, 2025, the Company had bank loans and other borrowings totaling RMB3.6 billion (US$508.4 million).

About Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles (“GAAP”), Concord Medical uses certain non-GAAP measures. Concord Medical presents the non-GAAP measure of adjusted EBITDA, which is defined in this announcement as net loss plus interest expenses, net, income tax expenses, depreciation and amortization and other adjustments. Other adjustments include foreign exchange loss, net, other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment. Furthermore, adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.

About Concord Medical

Concord Medical Services Holdings Limited is a healthcare provider featuring a full cycle of premium oncology services including cancer diagnosis, treatment, education and prevention. The Company focuses on providing multidisciplinary cancer care in all aspects of oncology healthcare services in its cancer hospitals and equipping them with technologically advanced equipment such as the state-of-the-art proton therapy system. The Company is striving to improve the quality and accessibility of cancer care through its network of self-owned cancer hospitals and clinics as well as partnered hospitals across China. For more information, please see http://ir.ccm.cn

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company’s control and based upon premises with respect to future business decisions, which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

 

 

Concord Medical Services Holdings Co., Ltd.

Consolidated Balance Sheets

(in thousands)

December 31,

2024

June 30, 2025

RMB

RMB

US$

(Audited)

(Unaudited)

(Unaudited)

ASSETS

Current assets

Cash and cash equivalents

216,224

177,389

24,763

Short-term investment

134,621

Restricted cash, current portion

20,758

20,216

2,822

Accounts receivable, net

51,168

57,360

8,007

Prepayments and other current assets, net

527,760

756,672

105,627

Inventories

33,441

13,691

1,911

Total current assets

983,972

1,025,328

143,130

Non-current assets

Property, plant and equipment, net

3,704,325

3,684,147

514,287

Right-of-use assets, net

520,817

507,849

70,893

Goodwill

572,216

572,216

79,878

Intangible assets, net

292,142

273,976

38,246

Deposits for non-current assets

174,883

210,055

29,323

Long-term investments

472,166

457,016

63,797

Other non-current assets

5,867

2,878

402

Total non-current assets

5,742,416

5,708,137

796,826

Total assets

6,726,388

6,733,465

939,956

LIABILITIES AND EQUITY

Current liabilities

Accounts payable

199,394

112,190

15,661

Accrued expenses and other liabilities

846,194

904,149

126,214

Income tax payable

1,623

16,416

2,292

Operating lease liabilities, current

45,448

47,061

6,569

Short-term bank and other borrowings

649,680

611,708

85,391

Long-term bank and other borrowings, current portion

383,016

762,772

106,479

Total current liabilities

2,125,355

2,454,296

342,606

Non-current liabilities

Long-term bank and other borrowings, non-current portion

2,693,693

2,267,655

316,554

Deferred tax liabilities

82,870

80,134

11,186

Operating lease liabilities, non-current

138,894

133,332

18,612

Other long-term liabilities

67,827

76,028

10,613

Total non-current liabilities

2,983,284

2,557,149

356,965

Total liabilities

5,108,639

5,011,445

699,571

EQUITY

Class A ordinary shares

68

68

10

Class B ordinary shares

37

37

5

Treasury stock

(7)

(7)

(1)

Additional paid-in capital

2,169,693

2,230,839

311,413

Accumulated other comprehensive loss

(77,349)

(70,404)

(9,828)

Accumulated deficit

(4,372,832)

(4,399,967)

(614,212)

Total Concord Medical Services Holdings Limited shareholders’
deficit

(2,280,390)

(2,239,434)

(312,613)

Noncontrolling interests

3,898,139

3,961,454

552,998

Total equity

1,617,749

1,722,020

240,385

Total liabilities and equity

6,726,388

6,733,465

939,956

 

 

Concord Medical Services Holdings Co., Ltd.

Consolidated Profit & Loss

(in thousands, except for number of shares and per share data)

June 30,

2024

June 30, 2025

RMB

RMB

US$

(Unaudited)

(Unaudited)

(Unaudited)

Revenues, net of business tax, value-added tax and related
surcharges

Hospital

137,772

153,007

21,359

Network

81,038

47,608

6,646

Total net revenues

218,810

200,615

28,005

Cost of revenues:

Hospital

(173,963)

(157,192)

(21,943)

Network

(86,443)

(47,706)

(6,660)

Total cost of revenues

(260,406)

(204,898)

(28,603)

Gross loss

(41,596)

(4,283)

(598)

Operating expenses:

Selling expenses

(24,975)

(21,006)

(2,932)

General and administrative expenses

(131,173)

(119,361)

(16,662)

Operating loss

(197,744)

(144,650)

(20,192)

Interest expense

(68,668)

(87,660)

(12,237)

Foreign exchange loss, net

(30,269)

(1,906)

(266)

Interest income

5,990

4,574

639

Change in fair value of derivative liability

(108,777)

Income from equity method investments

6,070

7,477

1,044

Gain on disposal of subsidiaries

47,997

Other expenses, net

1,388

(894)

(125)

Gain on disposal of equity method investment

37,471

5,231

Changes in fair value of short-term investments

6,631

Loss before income tax

(337,382)

(185,588)

(25,906)

Income tax expenses

8,674

(19,784)

(2,762)

Net loss

(328,708)

(205,372)

(28,668)

Net loss attributable to noncontrolling interests

(156,450)

(178,237)

(24,881)

Net loss attributable to Concord Medical Services Holdings
Limited

(172,258)

(27,135)

(3,787)

Loss per share for Class A and Class B ordinary shares

Basic

(1.31)

(0.21)

(0.03)

Diluted

(1.31)

(0.21)

(0.03)

Weighted average number of class A and class B ordinary shares
outstanding:

Basic

131,053,858

131,053,858

131,053,858

Diluted

131,053,858

131,053,858

131,053,858

Other comprehensive loss, net of tax of nil

Foreign currency translation, net tax of nil

(6,273)

6,945

969

Total other comprehensive loss, net of tax

(6,273)

6,945

969

Comprehensive loss

(334,981)

(198,427)

(27,699)

Comprehensive loss attributable to noncontrolling interests

(156,450)

(178,237)

(24,881)

Comprehensive loss attributable to Concord Medical Services
Holdings Limited’s shareholders

(178,531)

(20,190)

(2,818)

 

 

Reconciliation from net income to adjusted EBITDA(*) (in RMB thousands, unaudited)

For the six months ended

For the six months ended

June 30, 2024

June 30, 2025

Net loss

(328,708)

(205,372)

Interest expenses, net

62,678

83,086

Income tax expenses

(8,674)

19,784

Depreciation and amortization

43,654

74,985

Other adjustments

83,030

(34,671)

Adjusted EBITDA

(148,020)

(62,188)

EBITDA margin

-68 %

-31 %

(*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net loss plus interest expenses, net, income tax
expenses, depreciation and amortization, and other adjustments. Other adjustments include foreign exchange loss, net,
other income, net, gain on disposal of equity method investment, gain on disposal of subsidiaries, change in fair value
of derivative liability, changes in fair value of short-term investments and gain on disposal of long-lived equipment.

 

Yifa’s Original Womenswear Brands Make a Bold Statement at WHITE Milano, Driving Deeper Engagement with Europe’s Fashion Industry

MILAN, Sept. 26, 2025 /PRNewswire/ — Coinciding with Milan Fashion Week Spring/Summer 2026, WHITE Milano, one of the world’s premier fashion showcases, formally opened at Superstudio Più (Via Tortona 27). Yifa Exhibition, the brand platform of Yifa Commercial Group, made a striking debut with a roster of emerging women’s fashion brands. Blending Eastern aesthetics with Milanese flair, the presentation marked a new chapter in the fashion dialogue between China and Europe.

Yifa's Original Womenswear Brands Make a Bold Statement at WHITE Milano, Driving Deeper Engagement with Europe's Fashion Industry
Yifa’s Original Womenswear Brands Make a Bold Statement at WHITE Milano, Driving Deeper Engagement with Europe’s Fashion Industry

The debut of the YIFA SHOWROOM was among the highlights of this year’s exhibition. Distinguished guests included:

  • Francesco Vassallo, Deputy Mayor of Milan
  • Zhang Daichen, Director of the Chinese Consulate General in Milan
  • Brenda Bellei, CEO of WHITE Milano
  • Massimiliano Bizzi, President and Founder of WHITE Milano
  • Zhao Huanqing, Chairman of MACRO Group, Italy
  • Xu Bin, Chairman of Yifa Commercial Group
  • Hou Cheng, Executive President of Yifa Exhibition

The opening ceremony also drew a wide audience of designers, fashion buyers, and media representatives from both China and Italy, who converged to witness a defining moment for Yifa’s womenswear brands on the global stage.

Inside the showroom, the featured brands span the full spectrum of categories—from cotton and linen to knitwear, down jackets, and shearling. Beyond the breadth of offerings, the collections highlight a sophisticated interplay of Eastern and Western aesthetics across design, fabrics, and craftsmanship, presenting the distinctive appeal of Chinese fashion in a refined and forward-looking way.

A thematic salon, Designed with Italy — Sino-Italian Value Co-Creation, featured Brenda Bellei, CEO of WHITE Milano; Lila, founder of French label Y’COO; Elisabetta Invernici, journalist of STILE ITALIA, along with industry commentators and veteran buyers. Discussions centered on how supply chain efficiency and cultural resonance can drive a shift from one-way manufacturing output to two-way value co-creation. Chinese expertise in digitalized supply chains and sustainable technologies is increasingly complementing Italy’s design vision and brand heritage. This synergy enables the co-creation of a more resilient and culturally resonant model for fashion product development, driving the transition from ‘Made in China‘ to ‘Designed with Italy‘.

Looking ahead, Yifa Commercial Group will engage global clients with an inclusive vision while enhancing its platform services to address the evolving needs of international markets. For more information about Yifa Commercial Group and its participating brands, please visit the official website: https://www.yffsc.com/en/.

iQIYI iJOY Conference 2025: Unveiling 400+ New Titles, Blending Hit IP with Long, Short and AI – Powered Content

BEIJING, Sept. 26, 2025 /PRNewswire/ — At its 2025 iJOY Conference in Shanghai held on September 25, iQIYI announced a lineup of over 400 new titles for the remainder of 2025 and 2026. The slate highlights the company’s strategy of building its popular IP across both long- and short-form, as well as AI powered content to redefine how stories are created and experienced in the digital age.

A Strategy for a New Era of Entertainment 

Founder and CEO Yu GONG framed this new era, noting, “The blend of long- and short-form content, combined with AI’s transformative impact, is fundamentally reshaping the entertainment world.” Reinforcing this vision, he emphasized: “iQIYI’s unwavering mission is to deliver emotional value to users at every touchpoint – both online and offline.” Premium IP will serve as a powerful focal element to provide these meaningful experiences.

As iQIYI evolves, it will continue to invest in its core long-form dramas while also accelerating the rise of vertical micro-dramas, which have become a key driver for audience growth.

GONG also unveiled plans for the opening of a new iQIYI Land and highlighted AI’s expanding role: “The moment when AI disrupts both long- and short-form content is imminent.” Positioned at the forefront of this change, iQIYI is seamlessly integrating AI into operations and production.

Founder and CEO Yu GONG
Founder and CEO Yu GONG

Building on a Strong 2025 Slate 

In 2025, iQIYI’s content ecosystem has shown strong performances across formats. Flagship dramas such as “Drifting Away”, “Feud”, “Coroner’s Diary”, and “This Thriving Land” have consistently attracted strong viewership. iQIYI’s micro-drama library has grown to over 20,000 titles, while the company’s original variety shows account for four of the top ten programs by viewership market share till now. The film division also saw success, with summer hits like “The Shadow’s Edge” surpassing 1.2 billion yuan at the box office.

At the event, Chief Content Officer Xiaohui WANG explained that iQIYI’s success stems from a creative philosophy focused on developing unique IP. This has translated to producing a wide range of diverse, high-quality content across all genres and categories. As WANG said, “In every genre, every category, every content segment, iQIYI commits fully and wholeheartedly, never neglecting any area.”

WANG further noted that central to this strategy is that, “Premium IP needs to be centered on emotion and supported by ideals”. By developing multi-dimensional characters, the company aims to generation divides, expand female narratives beyond traditional stereotypes, craft diverse male roles that resonate with modern audiences. This comprehensive approach ensures iQIYI’s content remains vibrant, fresh and deeply engaging, enabling the platform to meet evolving audience tastes while fostering stronger emotional bonds.

Chief Content Officer Xiaohui WANG
Chief Content Officer Xiaohui WANG

A Multi-Genre Slate for Every Audience 

iQIYI also detailed its upcoming content strategy across key formats, the drama lineup includes major long-form dramas such as “Strange Chronicles of Tang”, as well as new titles from beloved “Theater” brands covering suspense, romance, and more, alongside a growing slate of micro dramas designed for mobile views. For variety shows, the 2026 which slate is organized into four main genres – gaming and entertainment, talent competitions, lifestyle shows, and opinion talk shows – supported by two additional lifestyle and emotional subgenres. Featuring returning hits like “The Blooming Journey 2” and new originals.

And in sports, iQIYI will continue to broadcast premier football leagues across Asia and Europe, major tennis and golf tournaments, and the 2026 FIFA World Cup, supported by original programming such as “Unbiased Football Guide”. The strategy also includes expanding iQIYI’s IP ecosystem into films, animations, kids’ programming, and documentaries to cater to a wide range of audience interests.

Extending IP Engagement Offline with Immersive Experiences

iQIYI is also expanding its IP into offline immersive experiences. Following Yangzhou and Kaifeng, a new iQIYI Land is planned for Beijing’s Wangfujing district, allowing fans to engage directly with their favorite shows and characters. The company’s network of immersive theaters has also grown to 58 venues across 31 cities, enriching storytelling with multi-sensory experiences beyond the screen.

AI as a Creative Partner 

A key highlight was the launch of the “Peter Pau × iQIYI AI Theater” by WANG and Oscar-winning Cinematographer Peter Pau. The initiative invites global creators to develop AI-driven films with the theme “Your Vision, The Next Dimension”. Fifteen exceptional projects will be selected for official production and are slated to premiere on iQIYI in early 2026.

Senior Vice President Gang WU also explained how AI is transforming iQIYI’s marketing, enabling data-driven and interactive campaigns. The company uses AI to precisely match scenarios for brands and reach the right customers, aiming to foster deeper engagement and brand loyalty.

Senior Vice President Gang WU
Senior Vice President Gang WU

Contact:
iQIYI Press, press@qiyi.com

 

World’s First Commercially Available Hybrid-Architecture Humanoid Robot Moves Into Mass Production: Kepler Marks the Start of a New Industrial Era

SHANGHAI, Sept. 26, 2025 /PRNewswire/ — Shanghai Kepler Robotics Co., Ltd (“Kepler Robotics”) has announced the start of mass production for its K2 “Bumblebee” model, confirming through a recently released video that the world’s first commercially available hybrid-architecture humanoid robot has begun shipping to customers.

 

The start of large-scale production and deliveries marks a major step forward in the global commercialization of humanoid robotics. Kepler Robotics has transitioned the technology from research prototypes to fully market-ready systems. The achievement represents a key milestone not only for the company, but also for the humanoid robotics industry, signaling the beginning of its production-scale era worldwide. 

Mass Production and Commercial Rollout: Built on Strong Technical Foundations

The move into mass production for the K2 “Bumblebee” is more than a shift from research to manufacturing; it represents a structural change in how the global humanoid robotics sector is evolving.

The production video highlights the K2 “Bumblebee” executing a straight-knee bipedal gait, as well as assembly line operations, component testing, high/low-temperature environmental tests, system aging trials, obstacle navigation, thousands of hours of continuous uptime without failure, and dynamic performance evaluations—all confirming the model’s readiness for real-world deployment.

The K2 “Bumblebee” features a hybrid serial-parallel design that combines roller screw linear actuators with rotary actuators. This architecture provides enhanced stability, extended operating life, and optimized performance for industrial environments. Because of the system’s technical complexity and high development costs, only a limited number of robotics companies worldwide have reached this level. The successful rollout of the K2 “Bumblebee” demonstrates that Kepler Robotics has achieved mass production and delivery on a technological platform aligned with international leaders.

Scaling production has been enabled by Kepler Robotics’ success in solving core technical challenges. To achieve a human-like straight-knee gait, the R&D team conducted in-depth research into screw mechanics rather than adopting the more common quasi-direct-drive approach. The planetary roller screw—a precision transmission component that converts rotary to linear motion—offers high efficiency, precision, load capacity, smooth operation, and long-term durability. By integrating planetary roller screw linear motors with rotary motors for joint actuation, the K2 “Bumblebee” achieves fine-grained joint control, even while executing high-load and complex movements.

To achieve a more natural walking motion, Kepler Robotics has invested heavily in bridging the “Sim-to-Real” gap—the discrepancy between simulated and real-world conditions that can introduce dynamic inaccuracies, sensor noise, delays, and computational lag, complicating torque control. The R&D team applied reinforcement learning and imitation to train the robot. Through reinforcement learning, the robot learned human-like walking behaviors via simulation and iterative optimization. GPU-accelerated physics simulation enabled parallel training for thousands of robots, each exposed to varied parameters and environments, producing a robust walking control strategy. In imitation learning, a high-fidelity physics simulator allowed the robot to replicate human gait characteristics—including heel strike, toe-off, and coordinated limb movement. Reward strategies further guided the robot to emulate human motion patterns while optimizing for speed, energy efficiency, and resistance to external disturbances. 

Mass production and commercial deployment have now moved from ambition to reality. The concept of a “first year of mass production” for humanoid robots is now coming into clear focus, signaling a transition from a capital-driven phase to one defined by scalable market adoption and measurable customer value.

From Concept to Productivity: A Tool for Real-World Workflows

The K2 “Bumblebee” delivers competitive advantage by providing measurable value to customers, bringing the idea of “humanoid robots in the workplace” into practical, real-world use.

Purpose-built for industrial integration, the K2 “Bumblebee” achieves up to 81.3% energy efficiency with its hybrid architecture, allowing for up to eight hours of operation on a single charge. Its human-like straight-knee walking gait enables agile navigation and obstacle avoidance in complex spaces such as logistics centers and factory floors. With a dual-arm payload capacity of up to 30 kg, the system is capable of carrying, loading, and unloading tasks. It also incorporates a layered (VLA+) model to process semantic commands, enabling accurate execution of tasks including sorting, assembly, and guided tours. Ready for immediate deployment, the K2 “Bumblebee” is designed for logistics, manufacturing, R&D, government exhibitions, and specialized operations, delivering clear operational benefits.

The K2 “Bumblebee” is priced at RMB 248,000 per unit, breaking through the million-yuan threshold of prototype humanoid robots and significantly lowering barriers for large-scale adoption. This competitive price point makes advanced robotics accessible to a broader range of customers. 

Building an Industry Ecosystem: Scaling Adoption Across Sectors

To date, Kepler Robotics has signed framework agreements covering several thousand units, with total contract value in the hundreds of millions of yuan. Customers include companies in industrial services, data operations, exhibitions, smart manufacturing, and specialized applications.

Commercial rollout is just the starting point. The company is committed to accelerating the development of a global humanoid robotics ecosystem. Current barriers—such as fragmented standards, low deployment efficiency, and limited local service networks—continue to slow adoption. Kepler Robotics is partnering across the supply chain to establish an integrated “technology-to-market” strategy to overcome these challenges. Since early 2025, the company has completed three funding rounds, adding strategic investors including Tao Motor, Friend, Zhaofeng, Hanwei, Jirfine Intelligent Equipment, Veichi, and Keli Sensing. With a hardware-first approach, Kepler Robotics secures critical positions in the supply chain, ensuring stable component sourcing while driving down costs through scale production, making humanoid systems more accessible and cost-effective.

As humanoid robots move into operational environments, they are becoming essential nodes within industrial ecosystems. In manufacturing, the K2 “Bumblebee” can take on repetitive tasks; in specialized fields, it can execute high-risk operations, enhancing both productivity and safety.

Through ongoing innovation and deeper ecosystem collaboration, Kepler Robotics will continue reducing barriers to humanoid adoption—accelerating industry-wide deployment and enabling more organizations to realize the benefits of advanced automation. 

  

Eason Technology Limited Filed Annual Report on Form 20-F for Fiscal Year 2024 and Regained Compliance with the NYSE American

HONG KONG, Sept. 26, 2025 /PRNewswire/ — Eason Technology Limited (“Eason Technology” or the “Company”) (NYSE American: DXF), a company engaged in real estate operation management and investment, and digital technology security business, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2024 with the Securities and Exchange Commission (“SEC”) on September 24, 2025 and that it has received a letter from the NYSE American confirming that the Company has regained compliance with Section 1007 of the NYSE American Company Guide. The annual report can be accessed on the SEC’s website at http://www.sec.gov as well as on the Company’s investor relations website at http://www.fdvsglobal.com/index.php/index-show-tid-83.html.

The Company will provide a hard copy of its annual report containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to the Company’s IR Department at ir@dunxin.us.

The audited financial statements of the Company for the year ended December 31, 2024 included in the Form 20-F contained an audit opinion from its independent registered public accounting firm, which included a going concern emphasis of matter paragraph. This announcement is made pursuant to NYSE American Company Guide Section 610(b), which requires separate public announcement of the receipt of an audit opinion containing a going concern paragraph. This announcement does not represent any change or amendment to the Company’s consolidated financial statements or to its Annual Report on Form 20-F for the year ended December 31, 2024.

About Eason Technology Limited

Eason Technology is a company engaged in real estate operation management and investment and digital technology security business in Hong Kong, China. The Company was formerly a licensed microfinance lender serving individuals and SMEs in Hubei Province, China, but has suspended offering loans to its customers since 2020.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

 

WMI and Law Society of Singapore Launch Certification Targeting 6,500 Lawyers to Support Family Office Sector Growth


SINGAPORE – Media OutReach Newswire – 26 September 2025 – Singapore lawyers will soon be able to gain specialised skills in family office advisory through a strategic partnership between the Wealth Management Institute (WMI) and the Law Society of Singapore. This multi-year training initiative aims to equip Singapore’s 6,500 practising lawyers with specialised skills to serve the rapidly growing family office sector.

Training agreement signed on 26 September 2025, by Ms Foo Mee Har, Chief Executive Officer, Wealth Management Institute and Mr Samuel Chacko, Vice-President, The Law Society of Singapore. Witnessed by Ms Tan Lay Peng, Principal Director, Wealth Management Institute and Mr Alvin Chen, Executive Director and Chief Legal Officer, The Law Society of Singapore.
Training agreement signed on 26 September 2025, by Ms Foo Mee Har, Chief Executive Officer, Wealth Management Institute and Mr Samuel Chacko, Vice-President, The Law Society of Singapore. Witnessed by Ms Tan Lay Peng, Principal Director, Wealth Management Institute and Mr Alvin Chen, Executive Director and Chief Legal Officer, The Law Society of Singapore.

The partnership addresses a growing need for legal training in this area, as demand surges for specialised legal expertise amid the rapid expansion of Singapore’s family office landscape. The nation has witnessed exceptional growth in its family office sector, with single-family offices exceeding 2,000 by the end of 2024, over five times the number just five years ago. This growth mirrors Singapore’s broader wealth management success, with a year-on-year increase of 12.2% in assets under management (AUM) in 2024, surpassing SGD 6 trillion for the first time. As wealthy families seek increasingly sophisticated legal guidance, it is vital to create formal pathways for lawyers to develop the specialised knowledge required.

The legal profession’s involvement in family office advisory services has become increasingly critical as wealthy families require sophisticated guidance on complex cross-border structures, regulatory compliance, and succession planning. Family office legal counsel must navigate varied asset portfolios, multiple jurisdictions, and intricate family dynamics while maintaining the highest standards of discretion and professional ethics.

From 2026, WMI will offer Foundation and Advanced programmes covering topics from family office governance, wealth and succession planning, operations and management, anti-money laundering and compliance, ESG and international tax considerations.

Ms. Lisa Sam, President of the Law Society of Singapore, emphasised the strategic importance for the legal profession, “The collaboration with the Wealth Management Institute provides a structured platform to develop legal expertise in the family office and private wealth advisory sector. It aligns the legal profession’s capabilities with the evolving needs of Singapore’s wealth management ecosystem.

As the family office and private wealth advisory space continues to grow, this collaboration provides an important platform to ensure that the legal profession is well-positioned to support Singapore’s broader wealth management ecosystem.”

Ms. Foo Mee Har, CEO of WMI, remarked, “We are honoured to partner with the Law Society of Singapore to further strengthen the nation’s capabilities as Asia’s premier family office hub. Lawyers play an indispensable role in establishing governance frameworks, navigating cross-border legal complexities, managing succession planning, and safeguarding long-term family interests. Robust legal advisory is fundamental to the integrity and sustainability of family office structures. This certification is designed to equip lawyers with the specialised expertise required to serve as trusted advisors in an increasingly complex and globalised family office environment.”

The certification programme will draw on WMI’s established faculty network, which includes prominent lawyers among its faculty members and alumni. It will also be overseen by an Expert Panel with representation from the Law Society to ensure industry alignment and practical relevance.

The programme forms part of a broader initiative in continuing professional education (CPE), as all Singapore lawyers are now required to obtain three Mandatory Ethics Component (MEC) points annually. The certification will be fully accredited by the Institute of Banking and Finance Singapore (IBF), making it eligible for IBF-STS and SkillsFuture funding support.

This initiative builds on WMI’s established leadership in family office education through the Global-Asia Family Office (GFO) Circle, launched in 2021 with the support of the Economic Development Board (EDB) and the Monetary Authority of Singapore (MAS). The GFO Circle has grown to over 1,400 members, and WMI has recorded over 5,300 enrolments in its family office programmes to date.

Hashtag: #WMI

The issuer is solely responsible for the content of this announcement.

About WMI

Established in 2003, the Wealth Management Institute (WMI) is committed to building capabilities for investing in a better tomorrow. Founded by GIC and Temasek, our vision is to be Asia’s Centre of Excellence for wealth and asset management education and research.

WMI provides a comprehensive suite of practice-based certification and diploma programmes and collaborates with leading universities for master’s degrees. With over 17,000 annual enrolments, WMI serves a diverse community of professionals across Asia—including wealth and asset managers, family offices, and professionals in tax, legal, compliance, and financial regulation across more than 150 programmes. WMI is recognised as Singapore’s lead training provider for private banking and wealth management.

WMI helms the Global-Asia Family Office (GFO) Circle, a trusted network platform that builds capabilities and fosters community within the family office sector. The GFO Circle is supported by the Singapore Economic Development Board (EDB) and the Monetary Authority of Singapore (MAS). WMI also leads the Asia Centre for Changemakers (ACC), supported by Temasek Trust and the Philanthropy Asia Alliance (PAA). The ACC aims to build capacity and nurture a strong pipeline of active and informed changemakers with a focus on Asia.

About The Law Society of Singapore

The Law Society of Singapore is the representative body for all lawyers in Singapore. Established under the Legal Profession Act 1966, it works to uphold the honour and independence of the legal profession, promote the interests of its members, and ensure access to justice by the public. The Law Society provides guidance, education, and advocacy on matters of law, and engages in community outreach to improve legal awareness. Through its initiatives, the Law Society strives to maintain the highest standards of professional conduct and to contribute meaningfully to Singapore’s legal landscape. The mission of the Law Society is to serve its members and the public by sustaining an independent bar which upholds the rule of law and ensures access to justice.

Asia Pacific Enterprise Awards (APEA) 2025 Taiwan Honors Outstanding Leaders and Enterprises Shaping the Future of Business

TAIPEI, Sept. 26, 2025 /PRNewswire/ — The Asia Pacific Enterprise Awards (APEA) recently celebrated Taiwan’s visionary leaders and pioneering enterprises that are reshaping industries and championing sustainable growth. Organized by leading regional NGO Enterprise Asia, the prestigious Taiwan Chapter was staged on 25 September 2025 at the Grand Hyatt Taipei.

Asia Pacific Enterprise Awards (APEA) 2025 Taiwan Honors Outstanding Leaders and Enterprises Shaping the Future of Business
Asia Pacific Enterprise Awards (APEA) 2025 Taiwan Honors Outstanding Leaders and Enterprises Shaping the Future of Business

The awards ceremony was graced by the presence of Dr. Eugene Chien, Advisor to Enterprise Asia and Ambassador-at large for Climate Change and Sustainability, Republic of China (Taiwan); Ms. Aznifah Ghani, President of the Malaysian Friendship and Trade Centre in Taipei; Mr. Eko Wijanarko, Director of Investment Department of the Indonesian Economic and Trade Office to Taipei; and Dr. Niven Huang, Managing Director of KPMG Sustainability Consulting Company Limited, KPMG in Taiwan, the event’s Official Assurance Partner.

Embracing the theme ‘Showcasing Future-Ready Enterprises’, the APEA 2025 honored exceptional businesses and leaders in Taiwan who exemplify resilience, innovation, and strategic foresight, successfully future-proofing their organizations in the face of rapid technological and economic transformation.

A distinguished panel of judges meticulously assessed over 100 nominees, evaluating each entrepreneur and organization for their overall operational excellence, leadership, and business performance. Through this rigorous evaluation process, the most outstanding recipients were selected across four categories: Master Entrepreneur, Inspirational Brand, Fast Enterprise, and Corporate Excellence.

Since 2007, the Awards has been organized all over the region with past recipients comprising Taiwan’s Douglas Hsu of Far Eastern Group, Thailand’s Supaluck Umpujh of The Mall Group, Mainland China’s Xu RongMao of Shimao Group, Hong Kong’s Francis Lui of Galaxy Entertainment Group, TTC Vietnam’s Dang Van Thanh, Indonesia’s Hary Tanoesoedibjo of MNC Group, India’s Adi Godrej of Godrej Group, the Philippines’ Manuel Villar of Vista Land, and Cuckoo Malaysia’s Hoe Kian Choon.

“In an era of constant disruption, the enterprises that will thrive are those that challenge conventions, embrace transformative technologies, and create value beyond profits. These organizations recognize the interconnectedness of economies, societies, and the environment, and take bold steps to shape a sustainable and inclusive future.” stated Tan Sri Dr. Fong Chan Onn, Chairman of Enterprise Asia, in his inspiring welcome address.

Among the distinguished honorees in the Master Entrepreneur category were Ms. Huang, Fang-Yue, President of Excellence Optoelectronics Inc.; Ms. Nancy Hsu, President of Far Eastern Department Stores Ltd.; and Mr. Young Liu, Chairman of Hon Hai Technology Group (Foxconn) who exemplify remarkable vision, resilience, and leadership in guiding their organizations to greater success.

The Inspirational Brand Award recognized renowned names such as Far Eastern Big City Shopping Malls Co., Ltd. and Watsons Personal Care Stores (Taiwan). Forestar Brokerage Co., Ltd and Wei Zheng Construction Co., Ltd were recognized in the Fast Enterprise Category, while leading achievers in the Corporate Excellence Category included Global Mall Co., Ltd., Standard Foods Corporation, Unimicron Technology Corp., and Taiwan Shin Kong Security Co., Ltd.

The APEA 2025 Taiwan Chapter is supported by the Taiwan Institute for Sustainable Energy (TAISE), with KPMG Taiwan as the Official Assurance Partner. PR Newswire is the Official News Release Distribution Partner, and Commercial Times, Dailywire.asia, and SME Magazine are the Media Partners.

AWARD RECIPIENT LIST OF THE ASIA PACIFIC ENTERPRISE AWARDS 2025 TAIWAN 

MASTER ENTREPRENEUR CATEGORY

NAME

COMPANY

INDUSTRY

LAI HUNG

FOUNDER & CHAIRMAN

ARTISTIC BIOMEDICAL LIMITED COMPANY

HEALTHCARE, PHARMACEUTICAL & BIOTECHNOLOGY

LINDA LU

CHAIRMAN

AWESOME GROUP

EDUCATION & TRAINING

HUANG, FANG-YUE

PRESIDENT

EXCELLENCE OPTOELECTRONICS INC.

AUTOMOTIVE

PHILBY LEE

CHAIRMAN

FAR EASTERN BIG CITY SHOPPING MALLS CO., LTD.

RETAIL

NANCY HSU

PRESIDENT

FAR EASTERN DEPARTMENT STORES LTD.

RETAIL

RICK LIAO

CHAIRMAN

FORESTAR BROKERAGE CO., LTD

FINANCIAL SERVICES

WILLIAM TSAI

CHAIRMAN

GOLDEN INSURANCE BROKERS CO., LTD.

FINANCIAL SERVICES

YOUNG LIU

CHAIRMAN

HON HAI TECHNOLOGY GROUP (FOXCONN)

MANUFACTURING

DANNY YU

CHAIRMAN

INTEGRATED SERVICE TECHNOLOGY INC. (iST)

PROFESSIONAL & BUSINESS SERVICES

DR. WAYNE YANG

CEO & GENERAL MANAGER

IV TECHNOLOGIES CO., LTD

MANUFACTURING

JERRY LIU

GENERAL MANAGER

JD LOGISTICS CORP.

TRANSPORTATION & LOGISTICS

JOHN CHUANG

PRESIDENT

ONYX HEALTHCARE INC.

HEALTHCARE, PHARMACEUTICAL & BIOTECHNOLOGY

JACKY WU

PRESIDENT

SKYLINES GROUP

RETAIL

RICHARD WU

CHAIRMAN

TAIWAN SHIN KONG SECURITY CO., LTD.

PROFESSIONAL & BUSINESS SERVICES

MILTON KING (CHUNG-JEN, KING)

PRESIDENT

YATUNG READY MIXED CONCRETE CO., LTD

BUILDING MATERIALS

 

FAST ENTERPRISE CATEGORY

COMPANY

INDUSTRY

ALLEYPIN INTERACTIVE CO., LTD.

PROFESSIONAL & BUSINESS SERVICES

EXCELLENCE OPTOELECTRONICS INC.

AUTOMOTIVE

FORESTAR BROKERAGE CO., LTD

FINANCIAL SERVICES

LEADGENE BIOMEDICAL, INC.

HEALTHCARE, PHARMACEUTICAL & BIOTECHNOLOGY

WEI ZHENG CONSTRUCTION CO., LTD

CONSTRUCTION

 

INSPIRATIONAL BRAND CATEGORY

COMPANY

INDUSTRY

FAR EASTERN BIG CITY SHOPPING MALLS CO., LTD.

RETAIL

FAR EASTERN DEPARTMENT STORES LTD.

RETAIL

KONE ELEVATORS TAIWAN CO., LTD

MANUFACTURING

LINTES TECHNOLOGY CO., LTD.

MANUFACTURING

WAN JA SHAN BREWERY CO., LTD.

FOOD & BEVERAGE

WANG WEI COFFEE INTERNATIONAL CO., LTD.

FOOD & BEVERAGE

WATSONS PERSONAL CARE STORES (TAIWAN)

RETAIL

 

CORPORATE EXCELLENCE CATEGORY

COMPANY

INDUSTRY

EAGLE EDUCATIONAL & CULTURAL ENTERPRISES, LTD.

EDUCATION & TRAINING

FAR EASTERN BIG CITY SHOPPING MALLS CO., LTD.

RETAIL

FAR EASTERN DEPARTMENT STORES LTD.

RETAIL

GLOBAL MALL CO., LTD.

RETAIL

GOLDEN INSURANCE BROKERS CO., LTD.

FINANCIAL SERVICES

INTEGRATED SERVICE TECHNOLOGY INC. (iST)

PROFESSIONAL & BUSINESS SERVICES

IV TECHNOLOGIES CO., LTD

MANUFACTURING

JD LOGISTICS CORP.

TRANSPORTATION & LOGISTICS

ONYX HEALTHCARE INC.

HEALTHCARE, PHARMACEUTICAL & BIOTECHNOLOGY

STANDARD FOODS CORPORATION

FOOD & BEVERAGE

TAI FUNG TRADING CO.,LTD

ENERGY

TAIWAN SHIN KONG SECURITY CO., LTD.

PROFESSIONAL & BUSINESS SERVICES

TAIWAN VENA ENERGY DEVELOPMENT CO., LTD.

RENEWABLE ENERGY

TTY BIOPHARM COMPANY LIMITED

HEALTHCARE, PHARMACEUTICAL & BIOTECHNOLOGY

UNIMICRON TECHNOLOGY CORP.

ELECTRICAL & ELECTRONICS

VIATRIS PHARMACEUTICAL CO., LTD.

HEALTHCARE, PHARMACEUTICAL & BIOTECHNOLOGY

VOLKTEK CORPORATION

MANUFACTURING

WEI ZHENG CONSTRUCTION CO., LTD

CONSTRUCTION

YATUNG READY MIXED CONCRETE CO., LTD

BUILDING MATERIALS

UNIWILL INSURANCE BROKER CO., LTD.

FINANCIAL SERVICES

 

About Enterprise Asia
Enterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine towards sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are an investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs, and other organizations to promote competitiveness and entrepreneurial development, uplift the economic status of people across Asia, and ensure a legacy of hope, innovation, and courage for future generations. Please visit www.enterpriseasia.org for more information.

About Asia Pacific Enterprise Awards
Launched in 2007, the Asia Pacific Enterprise Awards is the region’s most prestigious award for outstanding entrepreneurship, continuous innovation, and sustainable leadership. The Award provides a platform for companies and governments to recognize entrepreneurial excellence, hence spurring greater innovation, fair business practices, and growth in entrepreneurship. As a regional award, it groups together leading entrepreneurs as a powerful voice for entrepreneurship and serves as a by-invitation-only networking powerhouse. The program has grown to encompass 16 countries/ regions and markets all over Asia. For further information, please visit www.apea.asia.

SeABank’s Ba3 credit ratings reaffirmed by Moody’s


HA NOI, VIETNAM – Media OutReach Newswire – 26 September 2025 – Moody’s, the world top three leading credit rating agencies, has issued its 2025 credit ratings for Southeast Asia Commercial Joint Stock Bank (SeABank). Accordingly, SeABank maintains its Ba3 ratings with outlook remains ‘Stable’.

SeABank’s Ba3 credit ratings reaffirmed by Moody’s

As of June 2025, SeABank maintains a Tangible Common Equity (TCE) ratio of 12.1%, the highest among similarly rated banks. Asset quality also remained broadly stable, with a non-performing loan (NPL) ratio controlled below 2%. Moody’s forecasts the Bank’s new delinquencies will remain low over the next 12-18 months, given its adequate track record in asset quality management.

Moody’s noted that SeABank’s profitability improved year-on-year in the first half of 2025, driven by the Bank’s enhanced operational efficiency. This reflects SeABank’s strengthened governance capacity, enabling the Bank to flexibly adapt to market conditions and maintain stable growth momentum.

Moody’s has reaffirmed SeABank’s Ba3 credit rating with a Stable outlook for the forth consecutive year. This reaffirmation demonstrates global recognition of SeABank’s governance capacity, solid financial foundation, and sustainable development strategies. The Bank’s reputation among domestic, international investors and partners is also reinforced. Furthermore, the ratings represent a positive signal for Vietnam’s financial market, as international institutions increasingly acknowledge the role of private joint stock commercial banks, such as SeABank, in the process of integration into the global economy.

In addition to strengthening its financial foundation, SeABank is taking the lead in supporting Vietnamese enterprises to expand into international markets, promoting green finance and green credit, and financing environmentally friendly projects. Through these initiatives, SeABank aims to make a tangible contribution to sustainable economic growth in line with Vietnam’s long-term development strategy.

As of June 30, 2025, SeABank’s total assets reached over VND379 trillion (approx. US$14.4 billion), further consolidating its position as one of the leading commercial joint stock banks in Vietnam, accompanying the development of Vietnamese enterprises and the national economy.

Hashtag: #SeABank

The issuer is solely responsible for the content of this announcement.